In advanced breast cancer, the phase III OlympiAD study of olaparib compared with physician’s choice of chemotherapy was conducted in patients with BRCA mutations and HER2 non-overexpressing metastatic breast cancer that had received ≤2 prior therapies in the advanced setting. The gene discussed is ERBB2; the disease is breast carcinoma.